Published in Br J Cancer on May 22, 2014
HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer (2015) 0.92
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front Endocrinol (Lausanne) (2015) 0.85
Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int (2015) 0.84
Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int (2015) 0.75
Molecular targets of luteolin in cancer. Eur J Cancer Prev (2016) 0.75
BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo. Onco Targets Ther (2015) 0.75
Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells. PLoS One (2017) 0.75
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 10.11
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci (2012) 4.96
Triple negative tumours: a critical review. Histopathology (2008) 4.94
The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell (2004) 4.29
Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res (1991) 4.12
Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 3.50
Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res (1999) 3.36
Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther (2007) 2.50
The IGF system and breast cancer. Endocr Relat Cancer (2001) 2.21
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther (2010) 1.70
Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res (1999) 1.63
Emerging targeted therapies for breast cancer. J Clin Oncol (2010) 1.61
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res (2007) 1.61
Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol (2003) 1.45
The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des (2007) 1.43
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem (2012) 1.41
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res (2011) 1.37
Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia (2011) 1.32
Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene (2010) 1.23
Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist (2009) 1.23
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res (2011) 1.22
PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol (2011) 1.21
The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene (2009) 1.20
Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res (2012) 1.11
The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol (2010) 1.02
Biallelic expression of the IGF2 gene in human breast disease. Hum Mol Genet (1996) 0.93
Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors (2011) 0.90
Targeted therapy of metastatic breast cancer. Clin Transl Oncol (2009) 0.89
Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells. Growth Factors (2011) 0.88
Targeting insulin-like growth factor in breast cancer therapeutics. Crit Rev Oncol Hematol (2012) 0.85
A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells. Prostate (2009) 0.84
The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab (2004) 0.83
Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One (2013) 0.83
Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer. Breast Care (Basel) (2011) 0.81